News & Analysis as of

Biotechnology › HKEx › Capital Markets

Skadden, Arps, Slate, Meagher & Flom LLP

Report on Hong Kong-Listed Biotech Companies - June 2024

Skadden, Arps, Slate, Meagher & Flom LLP on

点击此处阅读调查报告全文 Our fourth annual report on Hong Kong-listed biotech companies examines how the sector performed during the continuing challenging market conditions of the last full calendar year. Although the number of...more

Skadden, Arps, Slate, Meagher & Flom LLP

Report on Hong Kong-Listed Biotech Companies - April 2023

Skadden, Arps, Slate, Meagher & Flom LLP on

点击此处阅读调查报告全文 Our third annual report on Hong Kong-listed biotech companies examines how the sector performed during the challenging conditions for capital markets globally over the past 12 months. Although aggregate listing...more

Skadden, Arps, Slate, Meagher & Flom LLP

Hong Kong’s Exchange Improves Its Allure for Chinese Issuers

Skadden, Arps, Slate, Meagher & Flom LLP on

Despite the impact of COVID-19 and other recent developments in Hong Kong, the city’s role as a center for China-based companies to raise capital became even more important in 2020. The momentum of several trends that began...more

3 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide